Information bias arises when incorrect information about either exposure or outcome or any covariates is collected in the study. It can be either non-differential when it does occur randomly across exposed/non-exposed participants or differential when it is influenced by the disease or exposure status.
Non differential misclassification bias drives the risk estimate towards the null value, while differential bias can drive the risk estimate in either direction. Examples of non-differential misclassification bias are recall bias (e.g., in case controls studies cases and controls can have different recall of their past exposures) and surveillance or detection bias.
Surveillance bias (or detection bias)
Surveillance or detection bias arises when patients in one exposure group have a higher probability of having the study outcome detected, due to increased surveillance, screening or testing of the outcome itself, or an associated symptom. For example, post-menopausal exposure to estrogen is associated with an increased risk of bleeding that can trigger screening for endometrial cancers, leading to a higher probability of early stage endometrial cancers being detected. Any association between estrogen exposure and endometrial cancer potentially overestimates risk, because unexposed patients with sub-clinical cancers would have a lower probability of their cancer being diagnosed or recorded. This is discussed in Alternative analytic methods for case-control studies of estrogens and endometrial cancer (N Engl J Med 1978;299(20):1089-94).
This non-random type of misclassification bias can be reduced by selecting an unexposed comparator group with a similar likelihood of screening or testing, selecting outcomes that are likely to be diagnosed equally in both exposure groups, or by adjusting for the surveillance rate in the analysis. The issues and recommendations are outlined in Surveillance Bias in Outcomes Reporting (JAMA, 2011;305(23):2462-3)).
Time-related bias is most often a form of differential misclassification bias and is triggered by inappropriate accounting of follow-up time and exposure status in the study design and analysis.
The choice of the exposure risk window can influence risk comparisons due to misclassification of drug exposure possibly associated with risks that vary over time. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies (Clin Epidemiol 1994:47(2):183–89) considers the impact of the time-window design on the validity of risk estimates in record linkage studies. In adverse drug reaction studies, an exposure risk-window constitutes the number of exposure days assigned to each prescription. The ideal design situation would occur when each exposure risk-window would only cover the period of potential excess risk. The estimation of the time of drug-related risk is however complex as it depends on the duration of drug use, timing of ingestion and the onset and persistence of drug toxicity. With longer windows, a substantive attenuation of incidence rates may be observed. Risk windows should be validated or sensitivity analyses should be conducted.
Immortal time bias
Immortal time bias refers to a period of cohort follow-up time during which death (or an outcome that determines end of follow-up) cannot occur. (K. Rothman, S. Greenland, T. Lash. Pharmacoepidemiology, 3rd Edition, Lippincott Williams & Wilkins, 2008 p. 106-7).
Immortal time bias can arise when the period between cohort entry and date of first exposure to a drug, during which the event of interest has not occurred, is either misclassified or simply excluded and not accounted for in the analysis. Immortal time bias in observational studies of drug effects (Pharmacoepidemiol Drug Saf 2007;16:241-9) demonstrates how several observational studies used a flawed approach to design and data analysis, leading to immortal time bias, which can generate an illusion of treatment effectiveness. This is frequently found in studies that compare groups of ‘users’ against ‘non-users’. Observational studies with surprisingly beneficial drug effects should therefore be re-assessed to account for this bias.
Immortal time bias in Pharmacoepidemiology (Am J Epidemiol 2008;167:492-9) describes various cohort study designs leading to this bias, quantifies its magnitude under different survival distributions and illustrates it with data from a cohort of lung cancer patients. For time-based, event-based and exposure-based cohort definitions, the bias in the rate ratio resulting from misclassified or excluded immortal time increases proportionately to the duration of immortal time.
Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods (Am J Epidemiol 2005;162:1016-23) describes five different approaches to deal with immortal time bias. The use of a time-dependent approach had several advantages: no subjects were excluded from the analysis and the study allowed effect estimation at any point in time after discharge. However, changes of exposure might be predictive of the study endpoint and need adjustment for time-varying confounders using complex methods. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes (BMJ 2010; 340:b5087) describes how immortal time in observation studies can bias the results in favour of the treatment group and how they can be identified and avoided. It is recommended that all cohort studies should be assessed for the presence of immortal time bias using appropriate validity criteria. However, Re. ‘Immortal time bias on pharmacoepidemiology’ (Am J Epidemiol 2009; 170: 667-8) argues that sound efforts at minimising the influence of more common biases should not be sacrificed to that of avoiding immortal time bias.
Other forms of time-related bias
Time-window Bias in Case-control Studies. Statins and Lung Cancer (Epidemiology 2011; 22 (2):228-31) describes a case-control study which reported a 45% reduction in the rate of lung cancer with any statin use. A differential misclassification bias arose from the methods used to select controls and measure their exposure, which resulted in exposure assessment to statins being based on a shorter time-span for cases than controls and an over-representation of unexposed cases. Properly accounting for time produced a null association.
In many database studies, exposure status during hospitalisations is unknown. Exposure misclassification bias may occur with a direction depending on whether exposure to drugs prescribed preceding hospitalisations are continued or discontinued and if days of hospitalisation are considered as gaps of exposure or not, especially during hospitalisation when several exposure categories are assigned, such as current, recent and past. The differential bias arising from the lack of information on (or lack of consideration of) hospitalisations that occur during the observation period (called ‘immeasurable time bias’ described in Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008;168 (3):329-35) can be particularly problematic when studying serious chronic diseases that require extensive medication use and multiple hospitalisations.
In the case of case control studies assessing chronic diseases with multiple hospitalizations and in-patient treatment (such as the use of inhaled corticosteroids and death in chronic obstructive pulmonary disease patients), no clearly valid approach to data analysis can fully circumvent this bias. However, sensitivity analyses such as restricting the analysis to non-hospitalised patients or providing estimates weighted by exposable time may provide additional information on the potential impact of this bias: Immeasurable time bias in observational studies of drug effects on mortality. (Am J Epidemiol 2008;168 (3):329-35).
In cohort studies where a first-line therapy (such as metformin) has been compared with second- or third-line therapies, patients are unlikely to be at the same stage of the disease (e.g. diabetes), which can induce confounding of the association with an outcome (e.g. cancer incidence) by disease duration. An outcome related to the first-line therapy may also be attributed to the second-line therapy if it occurs after a long period of exposure. Such situation requires matching on disease duration and consideration of latency time windows in the analysis (example drawn from Metformin and the Risk of Cancer. Time-related biases in observational studies. Diabetes Care 2012;35(12):2665-73).
|10. Specific topics|
|Annex 1.||Guidance on conducting systematic revies and meta-analyses of completed comparative pharmacoepidemiological studies of safety outcomes|